Vallejo Casas, Juan AntonioSambo, MarcelLopez Lopez, CarlosDuran-Poveda, ManuelRodriguez-Villanueva Garcia, JulioSantos, Rita JoanaLlanos, MartaNavarro-Gonzalez, ElenaAller, JavierPubul, VirginiaGuadalix, SonsolesCrespo, GuillermoGonzalez, CintiaZafon, CarlesNavarro, MiguelSantamaria-Sandi, JavierSegura, AngelGajate, PabloGomez-Balaguer, MarcelinoValdivia, JavierPuig-Domingo, ManelGalofre, Juan CarlosCastelo, BeatrizVillanueva, Maria JoseArgüelles, IñakiOrcajo-Rincon, Lorenzo2023-05-032023-05-032022-06-30Vallejo Casas JA, Sambo M, López López C, Durán-Poveda M, Rodríguez-Villanueva García J, Santos RJ, et al. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study. Eur Thyroid J. 2022 Aug 11;11(5):e2101112235-0640http://hdl.handle.net/10668/20449Up to 30% of differentiated thyroid cancer (DTC) will develop advanced-stage disease (aDTC) with reduced overall survival (OS). The aim of this study is to characterize initial diagnosis of aDTC, its therapeutic management, and prognosis in Spain and Portugal. A multicentre, longitudinal, retrospective study of adult patients diagnosed with aDTC in the Iberian Peninsula was conducted between January 2007 and December 2012. Analyses of baseline characteristics and results of initial treatments, relapse- or progression-free survival ((RP)FS) from first DTC diagnosis, OS, and prognostic factors impacting the evolution of advanced disease were evaluated. Two hundred and thirteen patients (median age: 63 years; 57% female) were eligible from 23 hospitals. Advanced disease presented at first diagnosis (de novo aDTC) included 54% of patients, while 46% had relapsed from early disease (recurrent/progressive eDTC). At initial stage, most patients received surgery (98%) and/or radioiodine (RAI) (89%), with no differences seen between median OS (95% CI) (10.4 (7.3-15.3) years) and median disease-specific-survival (95% CI) (11.1 (8.7-16.2) years; log-rank test P = 0.4737). Age at diagnosis being Identification of early treatment-dependent prognostic factors for an unfavourable course of advanced disease is possible. An intensified therapeutic attitude may reverse this trend and should be considered in poor-performing patients. Prospective studies are required to confirm these findings.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Advanced differentiated thyroid cancerEpidemiological studyRadioiodine-refractory differentiated thyroid cancerRelapsing differentiated thyroid cancerRelapsing prognostic factorsSurvival prognostic factorsIodine radioisotopesPortugalSpainProgression-free survivalProspective studiesThyroid neoplasmsAdenocarcinomaChronic diseaseresearch article35900793open access10.1530/ETJ-21-0111PMC9422238https://etj.bioscientifica.com/downloadpdf/journals/etj/11/5/ETJ-21-0111.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422238/pdf